This article addresses the millions of heart failure patients worldwide that have a significantly increased risk of mortality because of functional mitral regurgitation (FMR). The article goes on to discuss the extensive clinical experience available for the Carillon device in treating FMR, advantages of the Carillon approach over alternative therapies, and highlights numerous patient groups that could benefit from treatment with the Carillon device. The authors conclude:

• The results of studies conducted to date suggest that FMR treatment with the Carillon device is both safe and effective in reducing both mitral regurgitation and left ventricular dysfunction.
• The short procedure time and the easy deployment of the device are certainly an advantage over other techniques available on the market.
• The prospective CARILLON US trial, currently underway, evaluates the effectiveness of the Carillon device on morbidity and mortality, and should validate the Carillon Mitral Contour System as a first-line interventional therapy.